Sano offers a disposable, low cost, Point-of-Care (POC) diagnostic platform with first focus on chronic wounds, quantitatively measuring wound biochemistry (enzymes called proteases) to personalize treatment, promote faster healing, and reduce treatment costs by 30-70%. In parallel, Sano will trial and commercialize an equine arthritis diagnostic for earlier revenue. Six other human and vet diseases that are characterized by elevated proteases will be pursued sequentially thereafter. Diabetes, obesity, and aging populations are trends affecting most societies in the world and all sharply increase the incidence of chronic wounds. Today, 6.5 million chronic wounds cost $25B to treat in the US alone--5x more chronic wounds globally--and WounDx (TM) will save over $3B in the US alone.